Anticancer Drugs Mesna Oncology Pharmacology Physiotherapy

Oral Mesna

In this article we will discuss Oral Mesna

In this article, we will discuss Oral Mesna. So, let’s get started.

Oral Mesna

Clinical studies comparing recommended intravenous and oral Mesna dosing regimens demonstrated incidences of grade 3 to 4 hematuria of <5%. Study 7 was an open label, randomized, two-way crossover study comparing three intravenous doses with an initial intravenous dose followed by two oral doses of Mesna in patients with cancer treated with ifosfamide at a dose of 1.2 g/m2 to 2.0 g/m2 for 3 to 5 days. Study 8 was a randomized, multicenter study in cancer patients receiving ifosfamide at 2.0 g/m2 for 5 days. In both studies, development of grade 3 or 4 hematuria was the primary efficacy endpoint.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.